Ground News

News about Johnson & Johnson

Stay current with all the latest and breaking news about Johnson & Johnson, compare headlines and perspectives between news sources on stories happening today. In total, 93stories have been published about Johnson & Johnson which Ground News has aggregated in the past 3 months.

Covered Most By

Local News Publishers

Suggest a source

Looking for a source we don't already have? Suggest one here.

Top Johnson & Johnson News

Johnson & Johnson · United States

With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short

71% Center coverage: 32 sources

Dizal Pharmaceutical’s Zegfrovy is now FDA approved for treating non-small cell lung cancer driven by a particular rare genetic signature. Johnson & Johnson drug Rybrevant already addresses this genetic signature as an earlier line of therapy, but Dizal executives contend their drug offers the potential for better safety and efficacy. The post With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short appe…See the Story

Cancer · United States

New Bispecific T-Cell Engager Approved for Multiple Myeloma

83% Center coverage: 6 sources

(MedPage Today) -- The FDA on Wednesday granted accelerated approval to linvoseltamab (Lynozyfic) for relapsed or refractory multiple myeloma after at least four prior lines of therapy. A B-cell maturation antigen (BCMA)-directed bispecific antibody...See the Story

FDA · United States

Regeneron Gets Long-Awaited FDA Okay for Myeloma Drug

Coverage: 2 sources

Regeneron's bid to join the crowded US market for BCMA-targeted bispecific antibodies for multiple myeloma has finally been realised See the Story

Apple Tree says its biotechs face ‘imminent collapse’; Advocates urge J&J to proceed with eye gene therapy; AbbVie buys in vivo CAR-T maker Capstan; and more

Happy July 4th weekend! We’ve got a condensed version of Endpoints Weekly for you this week, so let’s dive right into the biggest stories. First up, a key investor for Apple Tree Partners is allegedly ...Johnson & Johnson Read Article

J&J suffers a loss over 340B drug discount program

100% Center coverage: 1 sources

J&J argued the ruling contradicts the statute and allows for the continuing abuse and potential fraud that undermines the 340B program.Johnson & Johnson See the Story

Why Cybin's CEO sees RFK Jr. and J&J's ketamine clinics as keys to clinical psilocybin's mainstream moment

From the Grateful Dead’s tour bus to the FDA’s approval queue, from “turn on, tune in, drop out” to potentially “take two doses and see me in a year,” this is the improbable journey of psychedelics in 2025. We now live in a world where a ketamine analog marketed by Johnson & Johnson could provide… The post Why Cybin’s CEO sees RFK Jr. and J&J’s ketamine clinics as keys to clinical psilocybin’s mainstream moment appeared first on Drug Discovery a…Robert F. Kennedy Jr. · United States Read Article

Advocates urge J&J to ‘put everything on the table’ for gene therapy despite failed trial

For Lewis Winton, the world looks different from one eye. In the first few months after getting a gene therapy in his right eye, Winton kept covering his other eye with his hand. Winton, a ...Johnson & Johnson Read Article

How Funding Cuts Are Undermining Patient Recruitment In Clinical Trials - Data Intelligence

In a recent video interview with Applied Clinical Trials, Kyle McAllister, co-founder, CEO, Trially, discussed the impact of funding cuts on underrepresented populations in medical research, emphasizing the importance of diversity-focused research. He highlighted the challenges created by budget cuts, particularly in patient recruitment and retention, due to reduced support staff. McAllister noted that artificial intelligence (AI) and new techno…Johnson & Johnson · United States See the Story

J&J teams with Nvidia, Amazon on fund for AI surgery solutions

100% Center coverage: 1 sources

J&J is offering up to $100,000 in grant funding, mentorship and access to computing capabilities.Johnson & Johnson · United States Read Article

Oppenheimer Asset Management Inc. Buys 76,201 Shares of Johnson & Johnson (NYSE:JNJ)

100% Center coverage: 2 sources

Oppenheimer Asset Management Inc. increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 13.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 656,765 shares of the company's stock after acquiring an addBusiness See the Story

How a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’

100% Center coverage: 1 sources

J&J’s former head of R&D, now CEO of Parabilis Medicines, aims to remain above the biotech fray by taking on unique targets from which others have steered clear.Pharma · United States Read Article

News about Johnson & Johnson

News about Johnson & Johnson

Covered Most By

Local News Publishers

Top Johnson & Johnson News

With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short

New Bispecific T-Cell Engager Approved for Multiple Myeloma

Regeneron Gets Long-Awaited FDA Okay for Myeloma Drug

Apple Tree says its biotechs face ‘imminent collapse’; Advocates urge J&J to proceed with eye gene therapy; AbbVie buys in vivo CAR-T maker Capstan; and more

J&J suffers a loss over 340B drug discount program

Why Cybin's CEO sees RFK Jr. and J&J's ketamine clinics as keys to clinical psilocybin's mainstream moment

Advocates urge J&J to ‘put everything on the table’ for gene therapy despite failed trial

How Funding Cuts Are Undermining Patient Recruitment In Clinical Trials - Data Intelligence

J&J teams with Nvidia, Amazon on fund for AI surgery solutions

Oppenheimer Asset Management Inc. Buys 76,201 Shares of Johnson & Johnson (NYSE:JNJ)

How a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’

Covered Most By

Media Bias Breakdown

Breaking News Topics Related to Johnson & Johnson